Evidence map›Paper›PMID 29550520›Full record

ReviewNitric oxide : biology and chemistry2018

Nitric oxide and cyclic GMP functions in bone.

Hema Kalyanaraman, Nadine Schall, Renate B Pilz

Abstract readReview
In one paragraph

Review in Nitric oxide : biology and chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. A standardized extract ofFrontiers in endocrinology · 2023
    Article
  19. Article
  20. Protein Kinase G2 Is Essential for Skeletal Homeostasis and Adaptation to Mechanical Loading in Male but Not Female Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hema KalyanaramanDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093-0652, USA.
Nadine SchallDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093-0652, USA.
Renate B PilzDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093-0652, USA. Electronic address: rpilz@ucsd.edu.

Funding

Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosisR01AR068601 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PILZ, RENATE B · 2016 to 2020
$1.8M
Testing novel NO/cGMP-based bone-anabolic agents in mouse models of osteoporosisR21AR065658 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PILZ, RENATE B · 2015 to 2016
$375k
NIAMS NIH HHS R01 AR068601NIAMS NIH HHS R21 AR065658NIH HHS R01-AR068601NIH HHS R21-AR065658
6 · The paper itself

Abstract

Nitric oxide plays a central role in the regulation of skeletal homeostasis. In cells of the osteoblastic lineage, NO is generated in response to mechanical stimulation and estrogen exposure. Via activation of soluble guanylyl cyclase (sGC) and cGMP-dependent protein kinases (PKGs), NO enhances proliferation, differentiation, and survival of bone-forming cells in the osteoblastic lineage. NO also regulates the differentiation and activity of bone-resorbing osteoclasts; here the effects are largely inhibitory and partly cGMP-independent. We review the skeletal phenotypes of mice deficient in NO synthases and PKGs, and the effects of NO and cGMP on bone formation and resorption. We examine the roles of NO and cGMP in bone adaptation to mechanical stimulation. Finally, we discuss preclinical and clinical data showing that NO donors and NO-independent sGC activators may protect against estrogen deficiency-induced bone loss. sGC represents an attractive target for the treatment of osteoporosis.

Indexed as

AnimalsBone and BonesCyclic GMPHumansNitric OxideCyclic GMPNitric OxideBonecGMPEstrogen deficiencyMechanotransductionNitric oxideOsteoblastsOsteoclastsOsteoporosisProtein kinase GSoluble guanylyl cyclase

Identifiers

PMID29550520
PMCPMC9990405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.